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Traumatic spinal cord injuries result in impairment or even complete loss of motor, sensory
and autonomic functions. Recovery after complete spinal cord injury is very limited even in
animal models receiving elaborate combinatorial treatments. Recently, we described an
implantable microsystem (microconnector) for low-pressure re-adaption of severed spinal
stumps in rat. Here we investigate the long-term structural and functional outcome following
microconnector implantation after complete spinal cord transection. Re-adaptation of spinal
stumps supports formation of a tissue bridge, glial and vascular cell invasion, motor axon
regeneration and myelination, resulting in partial recovery of motor-evoked potentials and a
thus far unmet improvement of locomotor behaviour. The recovery lasts for at least
5 months. Despite a late partial decline, motor recovery remains significantly superior to
controls. Our findings demonstrate that microsystem technology can foster long-lasting
functional improvement after complete spinal injury, providing a new and effective tool for
combinatorial therapies.
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After a spinal cord injury (SCI), descending and ascendingaxons are interrupted resulting in subsequent loss ofsensory and motor functions. Severed axons initially
attempt to recover via sprouting reactions but spontaneous repair
is limited (see ref. 1). This is partially explained by inhibitory
factors, which accumulate in the glial lesion scar and compromise
regenerative responses2,3. Many factors contribute to the failure
of axonal regeneration within the central nervous system (CNS).
These include inflammatory reactions, an unfavourable balance
or insufficient amounts of permissive growth substrates and
neurotrophic factors, in addition to appearance of numerous
inhibitory molecules and catabolic mechanisms in the lesion area
that result in very little spontaneous axon outgrowth4–7. At the
same time, the loss of oligodendrocytes, demyelination of sur-
viving axons and loss of trophic support8–10 lead to further
damage and impairment of function. The lesion scar, inflam-
matory reactions and the release of inhibitors can be modulated
on a molecular basis, and such possibilities have led to the
development of numerous therapeutic approaches to treat
SCI5,9,11–28. In general, these approaches present only limited
possibilities to stabilise and re-adapt injured spinal tissue in
submillimetre range.
We have recently described a novel microconnector implant
(mechanical microconnector system (mMS)), which was devel-
oped for the purpose of re-adapting the separated stumps of
severely injured rat spinal cords29. The mMS device fosters sta-
bilisation and adaptation of the spinal cord stumps and mini-
mises the distance to be overcome by regenerating axons, while
offering the possibility to infuse pharmacological substances
directly into the lesion centre via internal microchannels. The
mMS connector system is adjustable in size, shape and material.
The complete transection of the spinal cord is a very severe
injury model. To date, experimental treatments can, to our
knowledge, achieve no or only low degrees of biologically relevant
locomotor function recovery following this type of lesion (see, e.g.
refs. 30–36). Here we show that, after acute severe damage of rat
spinal cord by a complete transection at thoracic level T9, mMS
implantation results in a significant increase in axonal regenera-
tion across the lesion site, invasion of glial cells and myelination
of regenerating axons as well as neovascularisation throughout
the implant. Most importantly, in contrast to spinally transected
(TX) control rats, the mMS-treated animal group revealed a
significantly improved locomotor recovery that persisted for at
least 5 months.
The lesion model of complete transection of the spinal cord
was chosen for the present proof-of-principle study because it is
the only model that provides unequivocal evidence for axonal
regeneration. Less severe types of injury (for example, contusion
models) generally result in a better functional recovery but at the
same time raise the question whether observed improvements are
the result of true axonal regeneration or rather compensatory
sprouting and functional plasticity. For future preclinical and
clinical applications of the mMS device, less severe lesion models
will be included.
Here we show the long-term outcome following micro-
connector implantation after complete spinal cord transection.
Re-adaptation of spinal stumps supports tissue restoration, ben-
eficial cell invasion, motor axon regeneration and myelination,
leading to a partial recovery of motor-evoked potentials (MEPs)
and significantly improved locomotor behaviour.
Results
Biocompatibility and integration of the mMS. To analyse the
extent of collagenous lesion scarring after injury, we visualised the
connective tissue matrix by trichrome staining (Fig. 1). Compared
to the dense collagenous lesion scar of completely TX control
animals at 4 months after injury, scarring is much less extensive
within the implanted device of mMS animals (Fig. 1a, b). How-
ever, the region around the mMS walls still contained some
collagenous scar (Fig. 1a). Immunohistochemically, no striking
increase in ED1+ populations of macrophages or microglia could
be observed (Fig. 1c, d). Reactive (glial fibrillary acidic protein
(GFAP)+) astrocytes were frequently detected in the mMS bridge
and lumen regions (Figs. 1d and 4a). Numerous neurofilament
(NF)+ axon profiles were detected in the mMS lumen (Fig. 1e),
whereas much less were found in the lesion centre of TX controls
(Fig. 1f; for complete overview of the lesion area of mMS vs. TX
animals at lower magnification, see Supplementary Figure 1). The
finding of von Willebrand factor (vWF)+ endothelial cells
revealed the presence of newly formed blood vessels in the lumen
of the implanted mMS and showed frequent association of
regenerating axon profiles with areas enriched in blood vessels
(Fig. 1g). The mMS was well incorporated into the TX spinal cord
maintaining its normal diameter (Fig. 1i), whereas spinal cord
diameter shrinks in control animals (Fig. 1j).
Axon regeneration into and beyond the mMS. Since many
axonal populations are recognised by general markers for NF, we
analysed regenerated axons in more detail by using immunohis-
tochemistry and axonal tracing techniques. Various descending
motor axon populations (serotonergic, 5-hydroxytryptamine (5-
HT); catecholaminergic, tyrosine hydroxylase (TH)) were inves-
tigated immunohistochemically. In addition, intra-spinal rostral
biotinylated dextran amine (BDA) tracing, and anterograde cor-
ticospinal tract (CST) BDA tracing were used to unambiguously
detect regenerated descending axons. 5-HT and TH stainings
were chosen as examples for axonal populations that are involved
in locomotor function. 5-HT+ and TH+ axon profiles were
detected both in the mMS lumen and in the adjacent caudal
spinal cord (Fig. 2a–f). Quantification revealed that substantially
more axons had regenerated across the mMS-implanted lesion as
compared to the TX injury alone (Fig. 2g, h; Supplementary
Figure 2). Despite the possibility that some of the detected 5-HT-
and TH-positive axons might be derived from serotonergic or
catecholaminergic propriospinal interneurons37–39, the observed
differences show that mMS implantation led to a detectable three-
fold increase in these motor axon profiles in the caudal spinal
cord.
Intraspinal rostral BDA labelling to validate fibre regeneration
proved that re-adaptation of the spinal stumps by the mMS
supports axon growth not only into but also across the lesion site.
The tracer is taken up by axons, which pass through the site of the
BDA injection rostral to the lesion. We found that significantly
more BDA-labelled axons were able to grow into the caudal
spinal cord of mMS animals compared to TX controls (Fig. 3a, b).
Following cortical BDA anterograde tracing in three mMS
animals, we found that even CST axons, which are known for
their poor regenerative capacity, grew across the mMS bridge into
caudal spinal cord areas (Fig. 3c, d).
Schwann cell association and myelination of regrown axons in
the mMS. Numerous S100+/GFAP− Schwann cells were detected
in the mMS lumen (Fig. 4a) and often (but not always) appeared
in close proximity to axons (Fig. 4b, Suppl. Figure 3). Interest-
ingly, at 5 months many axon profiles in the mMS lumen
appeared to be myelinated as indicated by myelin basic protein
(MBP) immunoreactivity (Fig. 4c). Positive staining for myelin
protein zero (P0), a specific marker of Schwann cell myelin,
further indicates that most, if not all, of the detected myelin in the
mMS belonged to Schwann cell-like cells (Fig. 4d). Axonal
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ensheathment by compact myelin derived from basement
membrane-bearing Schwann cell-like cells as well as wrapping of
single axons by pro-myelinating Schwann cell-like cells was
confirmed by transmission electron microscopy (Fig. 4e, f). Co-
localisation of P0 immunoreactivity with TH+ or 5-HT+ neurons
was not detected in the analysed areas, suggesting that the mye-
linated axons presumably emanate from other fibre populations.
Improved locomotion after mMS implantation. Functional
locomotor outcome was tested in the open field once per week
over a period of at least 5 months. During the entire observation
period, animals of the mMS-implanted group performed better
with respect to locomotor outcome than TX control animals. In
the regular Basso–Beattie–Bresnahan (BBB)40 open field test,
mMS animals reached scores of 8–10.5, relating to sweeping
movements of both hindlimbs or to occasional weight-supported
stepping without forelimb–hindlimb coordination, whereas the
control group reached BBB scores of 2–4 only. However, the
regular BBB open field test—which was originally developed for
moderate thoracic contusion injuries—does not allow any further
discrimination and evaluation of subtle improvements that occur
after TX. Therefore, we used a recently modified BBB (mBBB)
score, which is better suited for rats with a complete transection
of their thoracic spinal cord41.
Animals of the mMS group reached considerably higher mBBB
scores than controls (Fig. 5). This is revealed both by the scatter
diagrams (Fig. 5a, b) showing the performance on the level of
individual animals and by mBBB threshold analyses (Fig. 5c). All
mMS animals reached the lowest threshold of mBBB 5, and
notably higher percentages of mMS compared to TX animals
reached the threshold of mBBB 10 (66 vs. 12.5%), respectively.
While six rats (50%) of the mMS-treated group achieved a
maximum mBBB score of ≥15, only one control animal (12.5%)
reached an mBBB score of 15. Four animals (33%) of the mMS
group, but none of the controls, were able to reach the highest
threshold of mBBB 20 (Fig. 5a–c). The latter four mMS animals
were by far the best performers and, indeed, were the first
reaching or passing a locomotor score of mBBB 15 within
4–7 weeks after treatment (Fig. 5b). Interestingly, we also noticed
a correlation between locomotor improvement and preservation
of the spinal cord tissue and diameter as provided by the mMS
(examples in Fig. 1i, j; also see Fig. 6).
The average performance of the two animal groups throughout
the entire open field study is summarised in Fig. 5d. At 4 weeks
after mMS implantation, the animals achieved mean mBBB
scores of 4 (“occasional right–left alternation of the hindlimbs
with weak amplitude”). After 7 weeks, mMS animals reached
mean mBBB scores of ≥10, indicating that the movements of their
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Fig. 1 mMS histocompatibility and integration (5 mpo). a, b Trichrome staining of the lesion area (rostral to the left). Note the loss of tissue and the dense
scar (asterisk) in the injury centre of TX animals. The mMS animals exhibit a less condensed scar especially in the mMS lumen (Lu); scarring is evident
especially in the outer border regions of the implant; arrows: staining artefacts resulting from tissue creasing during processing. c, d At the analysed time
points, no clear differences in the amount of ED1+ macrophages were detected between mMS and TX control animals with immunohistochemical
stainings: while in TX controls these cells accumulated particularly in the lesion centre (asterisk), in mMS animals more ED1+ cells were detected in the
border regions of the mMS compared to the lumen (Lu). e, f After longer post-implantation time periods, the mMS lumen was filled with numerous NF+
axon profiles, whereas the lesion area of TX controls is not attractive for regenerating nerve fibres. g Areas rich in vWF+ blood vessels (arrows) within the
mMS lumen frequently reveal numerous profiles of regrowing axons in close apposition. h Schematic representation of one of the complementary halves of
the implantable microconnector system. i, j Representative photographic images of spinal cord specimen of an mMS animal (i) and TX control (j); cystic
cavitation and flattening (asterisk) as well as increased transparency of spinal tissue are recognisable in the lesion area of control animals correlating with
decreased mBBB scores (red/green numbers represent the maximum mBBB scores of the respective animals). Scale bars: a, b: 1 mm, c, d: 500 µm,
e, f: 100 µm, g: 50 µm
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support. Subsequently, the animals scored increasing mBBB
values and plateaued at mean mBBB 13–14 (“occasional to
frequent right–left alternation of the hindlimbs with large
amplitudes and either some body weight (bw) support or some
plantar foot placement”) lasting for several weeks (weeks post-
opearation (wpo) 9–15). From week 6 onward until to the end of
the study, the mMS group performed consistently and signifi-
cantly better than the TX control group. Throughout the entire
observation period the average score of the TX control group
stayed below mBBB 6 (“frequent alternation of the hindlimbs
with weak amplitude”). Although the locomotor scores of animals
in both the mMS and control groups started to decline in wpo 16,
the mMS animals continued to perform significantly better than
TX control animals until the end of the study (Fig. 5d).
Upon locomotor performance, the animals of the mMS-treated
group could be subdivided into “good performers” (7 rats; mBBB
≥15) and “poor performers” (4 rats; mBBB ≤10). Closer
inspection of the two subgroups revealed occurrence of large
cysts in three of the four poor performers compared to only one
of the seven good performers (Fig. 6a). Correspondingly, the
numbers of 5-HT+ and TH+ axon profiles in the caudal spinal
cord of the good performers was detected to be twice as high as
those of the poor performers (Fig. 6d). Surprisingly, one poor
performer, which exhibited high numbers of axon profiles in the
caudal spinal cord only, revealed a maximum mBBB score of 9.
This incongruity could be attributed to a large cyst, which was
detected adjacent to the rostral border of the mMS implantation
site (Fig. 6b, b’, c).
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Fig. 2 Axon quantification of 5-HT+ and TH+ profiles. a Schematic representation of the implant area with rostral and caudal spinal cord and mMS lumen
(Lu) and bridge (Br) regions for better orientation. b, e Examples of axon ingrowth into the mMS; c example of axon outgrowth. d, f Examples of axon
profiles (arrows in f indicate TH fibres) that could be detected in the caudal stump of the spinal cord of mMS animals. g Quantification of 5-HT+ profiles
per section in the caudal stump; mean ± SEM; **p= 0.005; Mann–Whitney U test. h Quantification of TH+ profiles per section in the caudal stump, mean ±
SEM; *p= 0.023; Mann–Whitney U test. Scale bars: b, c: 100 µm, d, e: 50 µm, f: 20 µm
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Locomotor improvement observed in mMS animals compared
to control rats could be underscored by electrophysiological
recordings (Fig. 7) in a separate experiment. In TX control
animals (N= 4), which also revealed strong MEP signals prior
to the injury (Fig. 7a), no MEP signals could be detected at early
(1 wpo; Fig. 7b) or late post-injury time points (2–6 months post-
operation (mpo); Fig. 7c). Similarly, mMS-treated animals (N=
8) also revealed clear MEP signals prior to the injury (Fig. 7e) and
no MEP conduction at early post-treatment time points (1 wpo;
Fig. 7f), indicating the completeness of spinal transection.
However, at late post-treatment time points (2–6 mpo), weak
but clear MEP signals (18–105 µV) with a threshold of 15 µV
could be recorded from 7 mMS animals (Fig. 7g, d). Re-gained
MEP signals disappeared after re-transection of the spinal cord
(Fig. 7h).
Discussion
Following complete spinal transection, the functional locomotor
outcome of severely injured rats could be improved by low-
pressure mechanical re-adaptation and stabilisation of the stumps
using a biocompatible microconnector device, mMS, which
integrated well into the spinal cord, supported formation of a
vascularised tissue bridge and prevented a reduction of spinal
cord diameter. The mMS fostered tissue preservation and stabi-
lisation of the spinal cord around the lesion area, which corre-
sponded to high mBBB scores (see example in Fig. 1i). TX
controls frequently exhibited spinal cord lesion areas that con-
tained either cystic cavities or spinal cord tissue in the respective
area obviously vanished, likely due to secondary degeneration, as
recognised by the flattened and transparent appearance of spinal
cord specimens (see example in Fig. 1j). No cases of reduction in
spinal cord diameter were observed in mMS-treated animals.
Beneficial effects of tissue protection on functional outcome have
been demonstrated previously42,43.
Interestingly, bringing the severed spinal stumps in close
apposition merely by mechanical forces using the mMS was
sufficient to promote regeneration of severed axons into and also
beyond the lesion area. Regenerated axons were detected by NF
immunostaining within the mMS and by intraspinal anterograde
BDA tracing of descending axons as well as by anterograde
cortical tracing of CST axons. Beyond the lesion, traced axons
were identified in intact caudal spinal cord regions. Further
immunohistological characterisation revealed that both ser-
otonergic and catecholaminergic axon populations were among
the regenerated fibres. Our data indicate that, compared to the
low proportion of spontaneously regenerating serotonergic and
catecholaminergic axons in TX control animals, implantation of
the mMS resulted in significantly increased numbers (three-fold
increase) of the respective axon profiles in the caudal spinal cord.
The latter axon profiles could arise from the raphe nucleus or the
locus coeruleus, respectively, or originate from propriospinal
interneurons37–39. The detection of traced CST axons growing
beyond the mMS into the caudal stump was intriguing because
corticospinal axons are known for their poor regenerative
capacity.
Regenerated axons were frequently associated with blood
vessel-rich areas in the mMS lumen, suggesting a beneficial effect
of angiogenesis on axon growth. It is known that blood vessels are
necessary for tissue regeneration and for supply and exchange of
nutrients as well as chemical signalling and thus considered vital
for repair and survival of regenerating nerve fibres44–46. More-
over, blood vessels have even been shown to serve as tracks to
direct migrating Schwann cells in regenerating peripheral nerve47.
This view is in line with our observation that regenerating axons
within the lumina of mMS devices were in close association with
Schwann cells, which are known to foster axon regrowth48,49, and
most likely myelinate the regrown axons, later, as revealed by
immunohistochemistry and transmission electron microscopy.
Abundant P0 immunoreactivity in combination with basement
membranes surrounding the myelinating or pro-myelinating glial
profiles unequivocally identify a Schwann cell-like phenotype of
still uncertain origin. It is possible that the dural rupture caused
by the transection injury may allow peripheral Schwann cells—
presumably originating from adjacent nerve roots—to invade the
lesion area50,51. Alternatively, the detected Schwann cells might
be derived from Schwann cell precursors52,53, originate from
bone marrow54, or emanate from endogenous CNS-resident glial
progenitors55.
Despite the fact that the original BBB open field analysis40 is
not well suited to animals with a total transection of the spinal
cord41,56, it is still applied in numerous animal studies that
employ complete spinal lesions. Numerous rodent studies pub-
lished in the past 15 years using original BBB scores reported
recovery rates after acute and sub-acute complete thoracic spinal
cord transection and various (single as well as combinatorial)
therapeutic treatments in the range of BBB 3–830–36, respectively,
all staying well below the plateau of locomotor recovery, reached
by implantation of the mMS (mBBB of 13–14, corresponding to a
BBB score of 10–10.5).
Our data demonstrate that mMS-implanted animals were able
to reach a hitherto unattained level of recovery in hindlimb
locomotor function following complete spinal cord transection.
Animals of the mMS-implanted group performed robustly and
(from wpo 6 onwards) significantly better in the open field than
control animals. The improved functional outcome of the mMS
group corresponds to the presence of increased numbers of
regenerating axons in the caudal spinal cord of treated animals.
Within 4 weeks after mMS implantation, the animals achieved
mBBB scores, which relate to and confirm the BBB scores that
were detected in our initial short-term mMS study29. After
7 weeks, mMS animals reached even higher mBBB scores, indi-
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Fig. 3 Anterograde BDA labelling of regenerating axons. a Example of
rostral intraspinal BDA-labelled axons, which have regenerated from the
mMS into the caudal spinal cord. The dashed line indicates the mMS/spinal
cord interface. b Quantification of axon profiles per section in the caudal
stump that have been traced via rostral intraspinal BDA labelling; mean ±
SEM. c, d Examples of BDA-labelled CST axon profiles at 0.5 mm (c) and
ca. 3 mm caudal from the mMS implant (d). Scale bars: a: 50 µm, c, d:
25 µm; Mann–Whitney U test: *p= 0.042
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frequent or consistent weight support. The animals continuously
scored increasing values for the following weeks and plateaued at
performance levels, which included occasional to frequent
right–left alternation of the hindlimbs with large amplitudes and
either some bw support or some plantar foot placement over
several weeks (wpo 9–15).
Very interestingly, upon closer inspection the mMS-treated
group appears to be split into extremely well-performing animals
(good performers) and those showing a course of recovery largely
resembling control animals (poor performers). A remarkable
proportion of the mMS animals (4 rats, 36%) even reached the
highest mBBB scores of mBBB 20–22 corresponding to a classical
BBB score of 10–11. TX control animals never reached average
mBBB scores higher than mBBB 6. As the only outlier, one
control animal showed a spontaneous but transient locomotor
score in the range of mBBB 10–15 between wpo 8 and 14. The
overall weak locomotor functional outcome observed in control
animals compared to the overall strong improvement found in
the mMS animals could possibly be explained by the lower
numbers of regenerating serotonergic and/or catecholaminergic
fibres regenerating in controls.
Further subdivision of the mMS-treated animals revealed the
negative influence of large cysts in or near the lesion area on
locomotor functional outcome: The good performers did—with
one exception—not exhibit the formation of a large cyst in the
lesion area and their locomotor functional outcome could be
attributed to the enhanced amounts of the detected regener-
ating axon profiles in the caudal spinal cord. The majority of
the poor performers, however, exhibited a large cyst adjacent to
the mMS implant, which might impede regenerative axon
growth and decrease the mechanical stability of the tissue.
Similar large cysts were commonly found in the lesion area of
the spinal cord of TX control animals. One animal of the mMS
subgroup of poor performers revealed surprisingly high num-
bers of both 5-HT+ and TH+ axon profiles despite formation
of a large cyst. Presumably due to the large cyst this animal
could not perform as well in the mBBB locomotor test as
animals of the good performer group, which lack cyst forma-
tion. Since the number of intraspinally BDA-labelled des-
cending axon profiles in the caudal spinal cord of both the
good- and poor-performing mMS-treated subgroups did not
differ, these axons, in contrast to the 5-HT+ and TH+ sub-
populations of fibres, are less likely to contribute to the
observed differences in locomotor outcome.
MEP recordings confirmed the long-term functional
improvement following mMS treatment. The fact that only mMS
animals, in contrast to TX controls, were able to recover their
MEP signal conduction to some, albeit low, degree during the
long-term recovery period further underscores the suitability of
the microconnector treatment to improve functional outcome.
The finding that the MEP signals disappeared after re-transection
of the spinal cord is in line with a potential functional role of
a S100 GFAP
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Fig. 4 Association of Schwann cells with regenerated axons in the mMS lumen. a Both Schwann cells (S100+/GFAP−) and astrocytes (S100−/GFAP+ or
S100+/GFAP+, respectively) invade the mMS lumen. b Close association of NF+ axons with S100+ Schwann cells. c Co-staining of NF and MBP indicates
myelination of axons in the mMS lumen. d Numerous axons (TUJ1+) in the mMS lumen are myelinated with peripheral myelin (P0+). e Electron
micrograph of a myelinated regrown axon in the lumen of a mMS honeycomb. Note basal lamina (arrow), identifying the myelinating cell as Schwann cell-
like glial cell. M myelin. f Electron micrograph of an axon in the lumen of an mMS honeycomb, ensheathed by a pro-myelinating glial cell. A basal lamina
(arrow), identifies the ensheathing cell as a Schwann cell-like glial cell. M myelin. Scale bars: a: 100 µm; b, c: 20 µm; d: 50 µm; e, f: 1 µm
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axonal reconnectivity for the achieved locomotor improvement
after mMS treatment.
The late decline in locomotor scores starting at wpo 16 in both
the mMS treated as well as control group is not yet fully
understood. Muscle atrophy57–59 is likely to cause the decrease in
locomotor performance since leg muscle use is initially com-
pletely lacking after SCI and still remains rather low thereafter. In
a different study, we compared weight and girth of the tibialis
anterior muscle of SCI animals at 8 months after a complete
spinal cord transection and uninjured littermates. The compar-
ison of the average girth and weight revealed considerable—
nearly 50%—muscle atrophy following spinal transection [TX
animals (n= 18): 4.3 cm girth, 13.5 g weight; uninjured controls
(n= 3): 7.8 cm girth, 23 g weight]. On the other hand, mala-
daptive plasticity60 or degradation of transient synaptic contacts
due to axonal pruning could also be responsible for the observed
decline in functional outcome.
It has been reported that rehabilitative measures like tread-
mill training and enriched environment potentially preserve
and support residual or regained locomotor function after
experimental SCI60–62. Hence the late decline in locomotor
outcome we observed in our long-term behavioural study could
possibly be prevented in future by applying concomitant
treadmill training in addition to implantation of the micro-
connector. A comparable decline in locomotor function after
an initial recovery phase following treatment has been descri-
bed previously63. Moon et al. attributed the observed loss
of initial locomotor recovery after a prolonged time period of
approximately 3 months post-SCI and treatment to a lack of
hindlimb usage and a general decrease in locomotion, which
could be overcome by the provision of motor enrichment
housing instead of standard housing63.
Owing to its internal microchannel system for controlled local
drug delivery and cell infusion, the mMS microsystem is well
suited for a wide range of combinatorial therapies comprising
antibodies against repulsive molecules, iron chelators, trophic
factors, enzymes and other compounds64–77. The currently lim-
ited functional outcomes of preclinical molecular and cellular
therapies applied to severe/complete SCI could probably be
substantially improved in combination with the mMS micro-
connector device serving as a basic treatment. Future biode-
gradability and individual adaptation of the mMS to match shape
and size of individual spinal lesions as determined by imaging
techniques like magnetic resonance imaging scans, and fabrica-
tion of the device via three-dimensional printing technology offer
possibilities for both standardised and personalised medical
treatment of acute and chronic severe SCI patients.
Methods
mMS design. Design and fabrication of the implantable microconnector systems
(mMS) have recently been reported in detail29. Microconnectors used in this study
were fabricated with polymethyl methacrylate. Connector systems with small holes
(cf. ref. 29; see schematic representation in Fig. 1a) were used for the study
described here.
Experimental animals and surgical procedures. For this study, adult female
Wistar rats (HanTac:WH; Taconic and RjHan:W) weighing 230–250 g were used.
Animals were housed in groups of four animals per cage with food and water ad
libitum. Although over the course of the study all animals revealed slightly varying
degrees of weight gain, no difference was observed between mMS-treated and TX
control animals in this respect.
SCI and mMS implantation. Institutional guidelines for animal safety and comfort
were adhered to, and all surgical interventions including electrophysiological
recordings and pre- and post-surgical animal care were provided in compliance
with the German Animal Protection law (AZ 8.87–50.10.34.08.061, AZ
mBBB TX
























































































Fig. 5 Functional locomotor improvement after acute mMS implantation. a, b Scatter diagrams of the individual mBBB scores of the TX control rats and
mMS-treated animals. Each symbol represents an individual animal. Owing to the loss of animals (see online methods for details), the depicted diagrams
are based on the following numbers of animals per respective time point: TX, wpo 1–7: 9 rats, wpo 8–20: 8 rats; mMS: wpo 1 and 2: 12 rats, wpo 3–17: 11
rats, wpo 18–20: 10 rats. c mBBB threshold analysis; d Average mBBB scores over the 5 months (20 weeks) period, mean ± SEM (see individual data points
in a or b, respectively). Note the drop in the mBBB scores at later time points. Mann–Whitney U test: *p < 0.05, **p < 0.01 (p values: wpo 6: 0.02, wpo 7:
0.01; wpo 8: 0.01; wpo 9: 0.007; wpo 10: 0.007; wpo 11: 0.01; wpo 12: 0.009; wpo 13: 0.007; wpo 14: 0.008; wpo 15: 0.005; wpo 16: 0.03; wpo 17: 0.02;
wpo 18: 0.04; wpo 19: 0.02; wpo 20: 0.007)
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84–02.04.2011.A332, AZ 87–51.04.2011.A023, AZ 84–02.04.2014.A195, State
Office, Environmental and Consumer Protection of North Rhine-Westphalia,
LANUV NRW).
A complete thoracic spinal cord transection was performed at thoracic level T9.
Compared to partial injuries, this lesion model holds several advantages: it is highly
reproducible and leads to comparable degrees of functional loss in all animals.
Therefore, locomotor improvements can be detected and followed up very
accurately. Details of the performed surgical procedures have been described
recently78. In summary, following laminectomy of the vertebrae Th8 and Th9 and
subsequent complete transection of the thoracic spinal cord by a transverse cut
using fine eye scissors, the mMS was fixed and implanted into the tissue gap
between the severed stumps, as described78. Two small spatulas were used to
carefully pull the segments apart to ensure completeness of transection. After
suturing the dura mater above the mMS implant, the adjacent spinal cord stumps
were sucked into the lumen of the device via gentle negative pressure (200–250
mbar, 10 min). Finally, overlying connective and muscle tissues were sutured in
layers.
Control animals (TX) received a complete transection of the spinal cord and the
subsequent dura suture but no mMS implant. Both animal groups, which were
included in the locomotor functional study (TX vs. mMS), initially consisted of
N= 12 rats each. One TX animal was sacrificed in wpo 7 (TX) because it had
developed a bladder infection, which remained unresponsive to antibiotic
treatment. Three animals of the TX group died unexpectedly in the first and one
mMS animal in the second post-operational week. These animals most likely died
from post-surgical complications after the severe injury. One animal of the mMS
group died unexpectedly late in wpo 18 for unknown reasons.
Recording of MEPs. Under ketamine/xylazine anaesthesia, screws were implanted
into the skull of the rats, based on a protocol by Schlag et al.79. Briefly, after
opening the skin two holes (diameter ca. 1 mm) were drilled into the scull and
screws (outer diameter of shank 1.2 mm) were screwed into these holes. One screw
(positive pole) was implanted into the left hemisphere above the hindlimb region of
the sensorimotor cortex (2.4 or 2 mm lateral from the midline, Bregma −2.0 or
−2.5 mm; 0.75–1 mm depth). A second screw (negative pole) was implanted above
the cerebellum (0 mm lateral from the midline, Lambda −1.5 mm, 1–1.5 mm
depth). For MEP recordings, the rats were anaesthetised with ketamine (55 mg/kg
bw)/xylazine (5 mg/kg bw), intraperitoneally. The skin above the screws was re-
opened and custom-made electrode wires were coiled around the exposed screws.
For recording of MEPs, needle electrodes (MLA1204, AD instruments) were
inserted into the belly of the musculus tibialis anterior with a reference placed
subcutaneously (s.c.) into the sole of the paw. The grounding electrode was inserted
s.c. at the animal’s back (at the height of the hips). MEPs were recorded under light
anaesthesia (according to Zandieh et al.80). Stimulation and recording were per-
formed with a PowerLab26T (AD Instruments). Stimuli (duration 100 ms) were
increased in 1 mA steps starting at 1 mA until the resulting MEP showed no further
increase. Final MEP recordings were performed 1 or 2 days prior to sacrifice. Since
movements of the animal’s body could lead to false positive results (due to
movement of the needle electrodes), care was taken not to include corresponding
signals in the analysis.
Behavioural testing. Locomotor behaviour of animals was assessed weekly using a
modified version of the BBB open field score (mBBB) for complete spinal cord
transection41. To evaluate the locomotor outcome, each animal was observed in an
open field for 4 min by two observers, and its movements were rated accordingly.
Behavioural testing was carried out blinded to the treatment of the animals and was
performed over a time period of 5 months after the initial surgery.
Rostral intraspinal labelling of descending axons in the thoracic spinal cord.
Rostral intraspinal tracing with BDA (10,000 MW, 10%; Life Technologies) was
performed 1 week prior to sacrifice as described previously41. BDA was injected
into the spinal cord 3 mm rostrally to the lesion/implantation site of anaesthetised
animals. Injections (0.2 μl each) of BDA were applied at the following spinal
coordinates: In the midline at a depth of 1.5 mm (ventral funiculus), 0.8 mm
(dorsal CST) and 0.5 mm (cuneate and gracile funiculi) from the pia mater, and at
1.0 mm laterally from the midline on each side at depths of 1.2, 0.8 and 0.4 mm
(lateral funiculi) from the pia mater using a grease-sealed glass cannula attached to
a Hamilton syringe.
Anterograde CST tracing. Anterograde CST tracing was performed 3 weeks prior
to sacrifice. After craniotomy, the CST of anaesthetised animals was anterogradely
traced via eight small volume injections (0.2 μl each) of BDA into the sensorimotor
cortex of each hemisphere using the Kopf stereotactic frame and coordinates
previously described41,70.
Re-transection of the spinal cord. Three days prior to sacrifice, a complete
transection was performed adjacent to the caudal border of the lesion/mMS area of
3 mMS animals. Subsequently, the dura was sutured.
Tissue preparation. Tissue preparation for immunohistochemistry was performed
as previously described:41,70 The animals were anaesthetised with Narcoren®
(Merial) and transcardially perfused with ice-cold phosphate-buffered saline (PBS)
for 2 min and subsequently with 4% paraformaldehyde (PFA; Merck) for 15 min.
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Fig. 6 Occurrence of large cysts and caudal axon profiles in good vs. poor
performers of the mMS group. a Only 1 out of 7 good performers (14%)
compared to 3 out of 4 poor performers (75%) revealed a large central
cyst. b, b', c Large cyst formation (indicated by red arrows in b, b' and
asterisk in c) in the spinal cord of a poor performer (mBBB 9) that showed
high numbers of caudal 5-HT+ and TH+ axon profiles; the cystic cavity was
already apparent prior to tissue processing (photographic images in b, b').
d Quantification of axon profiles suggests a generally increased (doubled)
number of both 5-HT+ and TH+ profiles in the caudal spinal cord of the
good performers in comparison to poor performers, while no difference
between good and poor performers was detected regarding the numbers of
intra-spinally BDA-labelled axon profiles. Scale bar in c: 1 mm
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containing the lesion area were embedded and cut in paraffin (20 μm parasagittal
sections).
The extent of the SCI scar tissue was analysed via Masson’s trichrome
histological staining.
Immunohistochemistry. Immunohistochemical staining of paraffin sections was
preceded by deparaffinisation, and standard immunohistological protocols were
used for all staining procedures. Untreated sections and control sections lacking
primary antibody were analysed for evidence of auto-fluorescence. All sections for
immunohistochemical analyses were taken from animals with survival times of
5–7 months.
The following antibodies directed to the proteins mentioned were used: SMI312
(pan-axonal marker of phosphorylated NF; Covance, 1:1000), Neuronal Class III β-
Tubulin (TUJ1; Covance, 1:1500), glial fibrillary acidic protein (GFAP; Millipore,
1:1000), glial fibrillary acidic protein (GFAP; Dako, 1:1000), ED1 (Serotec, 1:1000),
MBP (Millipore, 1:50), P0 (Aves Labs, 1:100), 5-HT (Biologo, 1:30), TH (Abcam,
1:750), vWF (Dako, 1:1000), and S100β (S100; Sigma, 1:1000). Epitope retrieval
with citrate buffer was used for MBP, and epitope retrieval with protease was used
for vWF. Sections were stained with one of the antibodies listed above by standard
immunohistological protocols: Washing with PBS, blocking with 5% normal
donkey serum for 1 h at room temperature, incubation with first antibody in PBS/
5% normal serum overnight at 4 °C, washing with PBS, and incubation for 1 h with
Alexa 488- or 594-conjugated secondary antibody (Molecular Probes), respectively.
For BDA visualisation of anterogradely labelled axons, Oregon Green® 488
(Molecular Probes; 1:1000) was applied.
For histological trichrome staining, following deparaffinisation and rehydration,
sections were immersed in plasma stain solution A (containing acid fuchsin,
Xylidine Ponceau and acetic acid), solution B (phosphomolybdic acid solution) and
fibre stain solution C (containing Light Green SF yellowish and acetic acid) for
10 min each.
The sections were analysed and/or photographed with either a Keyence Biozero
8000 microscope or a Nikon Diaphot 300 fluorescent microscope or a Zeiss LSM
510 Meta confocal microscope.
Quantification of axon profiles. The quantification of axon profiles was per-
formed blinded to the treatment of the animals using sections from animals with a
survival time of 5–7 mpo. For quantification of 5-HT- and TH-positive axon
profiles in the spinal cord caudal to the lesion (an area of approximately 1 cm in
length starting from the lesion border was evaluated), on average 10 TH and 13 5-
HT immunostained 20 μm parasagittal sections from analogous regions were taken
per animal. On average, six sections from analogous regions of each of these
respective animals were used for the quantification of axon profiles that had been
labelled via rostral BDA injections. Sections were analysed using the ×20 objective
of a Nikon Diaphot 300 fluorescent microscope. As described in ref. 41, whenever
the identification of single axon profiles could not be ensured (e.g. in small
entangled axon bundles) the ×40 objective was used for confirmation. Axon pro-
files were counted under the microscope.
Transmission electron microscopy. For electron microscopic analysis, mMS of
operated rats were postfixed in perfusion fixative and cleaned from surrounding
connective tissues, followed by osmification and embedding in Epon41. Semithin
sections were prepared and inspected by light microscope to select internal
structures of the mMS containing nerve fibres. For ultrathin sections, mMS
material was trimmed away with a razor blade, sparing the lumen of the most
innervated honeycomb. Ultrathin sections were investigated by a ProScan Slow
Scan CCD (ProScan) camera mounted to a Leo 906 E electron microscope (Zeiss)
and the corresponding software iTEM (Soft Imaging System).
Statistics. StatPlus Software was used for the majority of the statistical intergroup
comparisons. For the MEP study, SigmaStat was used for the statistical analyses. As
reported in ref. 41, data sets were tested for significant deviations from statistical
normality using Shapiro–Wilk test (p= 0.05). Because this test revealed that the
distributions of the data were not normal, nonparametric Kruskal–Wallis test was
used for evaluation of significant intergroup differences in axon numbers. Non-
parametric tests are better suited for statistical analyses of data that contain out-
liers. The experimental groups were considered significantly different at p ≤ 0.05.
For the statistical analysis of the behavioural test results of animals with complete
spinal transection, a paired comparison was performed using the one-sided
Mann–Whitney U test. The experimental groups were considered significantly
different at p ≤ 0.05. For the electrophysiological analysis, the statistical method
used was Fisher Exact Test.
Data availability
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